Literature DB >> 6330301

Binding of [3H]imipramine to human platelet membranes with compensation for saturable binding to filters and its implication for binding studies with brain membranes.

O M Phillips, K M Wood, D C Williams.   

Abstract

Apparent specific binding of [3H]imipramine to human platelet membranes at high concentrations of imipramine showed deviation from that expected of a single binding site, a result consistent with a low-affinity binding site. The deviation was due to displaceable, saturable binding to the glass fibre filters used in the assays. Imipramine, chloripramine, desipramine, and fluoxetine inhibited binding to filters whereas 5-hydroxytryptamine and ethanol were ineffective. Experimental conditions were developed that eliminated filter binding, allowing assay of high- and low-affinity binding to membranes. Failure to correct for filter binding may lead to overestimation of binding parameters, Bmax and KD for high-affinity binding to membranes, and may also be misinterpreted as indicating a low-affinity binding component in both platelet and brain membranes. Low-affinity binding (KD less than 2 microM) of imipramine to human platelet membranes was demonstrated and its significance discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330301     DOI: 10.1111/j.1471-4159.1984.tb00924.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Effects of neonatal antithyroid treatment on brain [3H]-imipramine binding sites.

Authors:  A Vaccari
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

2.  3H-clonidine and 3H-yohimbine binding to glass fiber filters: implications for studies with platelet membranes.

Authors:  J E Piletz; A C Andorn; A Halaris
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  2-Nitroimipramine: a photoaffinity probe for the serotonin uptake/tricyclic binding site complex.

Authors:  L P Wennogle; R A Ashton; D I Schuster; R B Murphy; L R Meyerson
Journal:  EMBO J       Date:  1985-04       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.